附件 99.1

iBio报告财务结果 第一季度202年第一季度5 财务结果

·  非人灵长类动物研究中进行中的Advanced myostatin项目

2024年11月12日，加利福尼亚圣地亚哥（GLOBE NEWSWIRE）——iBio，Inc.（NYSEA: IBIO）今天报告了截止于2024年9月30日的第一季度财务业绩，并就其进展提供了企业更新。

​

在我们的财政第一季度，我们加强了与AstralBio的合作，制造和给非人灵长类动物注射了一种具有肌肉消耗和肥胖治疗潜力的首要分子 体内首席执行官兼首席科学官马丁·布伦纳博士表示：“在我们的财政第一季度，我们加强了与AstralBio的合作，通过聘请经验丰富的业务发展高管克里斯蒂·萨诺，进一步推进了肌肉消耗和肥胖等额外目标的早期研究。 这一举措对我们努力为抗体发展合作伙伴提供关键支持至关重要。 我们对我们的快速进展感到满意，并期待在未来几个月分享数据和进展，因为我们致力于将我们的药物管线推进到心脑血管疾病和肥胖的临床阶段。”

​

2025财政第一季度及最新企业动态更新：

​

​

2025财年第一季度财务业绩：

​

​

​

​

关于iBio，Inc。

iBio是一家以人工智能驱动的创新者，利用计算生物学和三维建模技术开发下一代生物制药产品，有望发现难以靶向的癌症和其他疾病的新抗体治疗方法。iBio的使命是减少药物失败率，缩短药物开发时间，并在最有前景的目标上开拓新领域。欲了解更多信息，请访问www.ibioinc.com.

​

Safe Harbor声明

Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the Company’s ability to build its pipeline in cardiometabolic diseases and obesity; the hiring of a business development executive by the Company resulting in critically enabling new partners in antibody development for challenging targets; the success of the Company’s development of next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes in prospectively enabling the discovery of new antibody treatments for hard to target cancers and other diseases; having initial data in early 2025 from non-the cGMP in vivo non-human primates (NHP) study; continuing to advance toward iBio’s goal of decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets, and iBio’s ability to build a pipeline in obesity and other cardiometabolic diseases. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to build its pipeline in cardiometabolic diseases and obesity; the ability to complete the non-cGMP in vivo non-human primates (NHP) study, the success of the Company’s development of next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes in prospectively enabling the discovery of new antibody treatments for hard to target cancers and other diseases; iBio’s ability to advance its goal of decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets, and the ability to build a pipeline in obesity and other cardiometabolic diseases, the ability to finance when needed and the risk factors described in the Company’s Annual Report on Form 10-k for the year ended June 30, 2024, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-k. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc.  specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

​

​

联系人：

iBio，Inc。
投资者关系
ir@ibioinc.com

Susan Thomas
iBio，Inc.
媒体关系
susan.thomas@ibioinc.com